Login| Sign Up| Help| Contact|

Patent Searching and Data

Document Type and Number:
WIPO Patent Application WO/2020/079993
Kind Code:
The present invention addresses the problem of providing a novel therapeutic drug for mental illness with abnormal neurodevelopment. Provided is an antipsychotic containing a Rho kinase inhibitor as an active ingredient. The antipsychotic can be utilized, for example, in the treatment of schizophrenia, autism spectrum disorders, bipolar disorder, or depression.

Application Number:
Publication Date:
April 23, 2020
Filing Date:
September 10, 2019
Export Citation:
Click for automatic bibliography generation   Help
International Classes:
A61K45/00; A61K31/551; A61P25/00; A61P25/18; A61P25/24; A61P43/00
Foreign References:
Other References:
GARCIA-ROJO, GONZALO ET AL.: "The ROCK Inhibitor Fasudil Prevents Chronic Restraint Stress-Induced Depressive-Like Behaviors and Dendritic Spine Loss in Rat Hippocampus", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, vol. 20, no. 4, 2017, pages 336 - 345, XP055702207
MEZIANE, HAMID ET AL.: "Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligophrenin-1 mouse model of intellectual disability", HUMAN MOLECULAR GENETICS, vol. 25, no. 11, 2016, pages 2314 - 2323, XP055702205
WROBEL, ANDRZEJ ET AL.: "Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 837, 30 August 2018 (2018-08-30), pages 127 - 136, XP085479383, DOI: 10.1016/j.ejphar.2018.08.027
INAN, SALIM YALCIN ET AL.: "Infralimbic cortex Rho-kinase inhibition causes antidepressant-like activity in rats", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 57, 3 March 2015 (2015-03-03), pages 36 - 43, XP055702199
LI, LI ET AL.: "Selective targeting of M-type potassium Kv7.4 channels demonstrates their key role in the regulation of dopaminergic neuronal excitability and depression-like behaviour", BRITISH JOURNAL OF PHARMACOLOGY, vol. 174, no. 23, December 2017 (2017-12-01), pages 4277 - 4294, XP055702195
SWANGER, SHARON A. ET AL.: "ROCK1 and ROCK2 inhibition alters dendritic spine morphology in hippocampal neurons", CELLULAR LOGISTICS, vol. 5, no. 4, 2015, XP055702191
KUSHIMA I. ET AL.: "High-resolution copy number variation analysis of schizophrenia in Japan", MOL PSYCHIATRY, vol. 22, 2017, pages 430 - 440
TRANSL PSYCHIATRY, vol. 8, no. 1, 19 July 2018 (2018-07-19), pages 129
CADINU D. ET AL.: "NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update", NEUROPHARMACOLOGY, vol. 17, no. 30584-1, 2017, pages S0028 - 3908
HOWES 0.MCCUTCHEON RSTONE J.: "Glutamate and dopamine in schizophrenia: an update for the 21st century", J PSYCHOPHARMACOL, vol. 29, 2015, pages 97 - 115
IBI D. ET AL.: "Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood", BEHAV BRAIN RES, vol. 206, 2010, pages 32 - 37, XP026709950, DOI: 10.1016/j.bbr.2009.08.027
JAVITT D. C. ET AL.: "Recent advances in the phencyclidine model of schizophrenia", AM J PSYCHIATRY, vol. 148, 1991, pages 1301 - 1308
KRYSTAL J.H. ET AL.: "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses", ARCH GEN PSYCHIATRY, vol. 51, 1994, pages 199 - 214
LIEBERMAN J.A.KANE J.M.ALVIR J.: "Provocative tests with psychostimulant drugs in schizophrenia", PSYCHOPHARMACOLOGY, vol. 91, 1987, pages 415 - 33
NEILL J.C. ET AL.: "Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism", PHARMACOL THER, vol. 128, 2010, pages 419 - 432, XP027445811, DOI: 10.1016/j.pharmthera.2010.07.004
TAMMINGA C.A. ET AL.: "Glutamate pharmacology and the treatment of schizophrenia: current status and future directions", INT CLIN PSYCHOPHARMACOL, vol. 10, 1995, pages 29 - 37, XP008084759, DOI: 10.1097/00004850-199509000-00005
VOLKOW N.D. ET AL.: "Neuropsychiatric disorders: investigation of schizophrenia and substance abuse", SEMIN NUCL MED, vol. 22, 1992, pages 254 - 267
WULAER B. ET AL.: "Repetitive and compulsive-like behaviors lead to cognitive dysfunction in Disc162-3/62-3 mice", GENES BRAIN BEHAV, 10 April 2018 (2018-04-10), pages e12478
Attorney, Agent or Firm:
HAGINO Mikiharu (JP)
Download PDF: